IL17A and arthritic joint disease: The combination of anti-IL-1β and anti-IL-17A antibodies significantly reduce the severity of arthritis, alleviates bone and cartilage damage, and down-regulates IL-1β, IL-6, IL-17A, IFN-γ, RANKL, and MMP-3 (104, 105).